Key Takeaways
- Recovery quarter, worst behind: Consolidated revenue of INR494 crores and EBITDA of INR83 crores mark a return to operational profitability after 6–9 months of regulatory scrutiny, with management stating the worst of the last 3 years' challenges is definitely behind.
- Pharma rebound delayed but underway: Supply resumptions and quality system upgrades drove a significant sequential volume improvement in Q3, though the recovery arrived a quarter late because U.S. FDA impact pushed H1 expectations into Q3.
- Crop Protection remains a drag: Overcapacity and Chinese pricing pressure continue to depress margins, with performance expected to stay stable on an annualized basis but offering no near-term uplift.
- Operating leverage story building for FY27–28: New products carry better gross margins than the company average, and as Animal Health, Personal Care, and NCE launches ramp on existing assets with only marginal balancing equipment, EBITDA should benefit from fixed cost absorption.
- What to watch next quarter: Whether the FDA warning letter period closure triggers a reinspection timeline, the pace of Personal Care commercialization, and any sign that Crop Protection pricing stabilizes.
Pharma Recovery & Quality Systems
- Supply resumptions on track: Volumes improved sequentially as quality management systems were strengthened, and the INR80 crores revenue reversal shifted from Q2 was fully adjusted in Q3 sales with no further adjustments anticipated.
- Remediation as permanent upgrade: Management frames the remediation not as a fix but as a permanent upgrade to organizational DNA, designed for long-term operational resilience; updates were submitted to the FDA on December 16 and February 9.
- FDA timeline: The 6-month warning letter period ends in the next 2 weeks, after which the company expects to hear back from the FDA on satisfaction with its remediation plan; reinspection timing remains unconfirmed.
- Dual-site validation underway: The company is aggressively executing a dual-site validation mandate for all critical APIs, which should strengthen supply chain redundancy and regulatory standing.
- Fact-finding review ongoing: A separate review of systems and processes is in progress, unrelated to numbers; management stated no further reversals are anticipated.
Sameer Hiremath: "I think the FDA is that we've had a 25-year track record. This is our first FDA inspection that we've had a not so of favorable inspection. So we know exactly what is to be done."
New Business Segments: Animal Health & Personal Care
- Animal Health master plan: Management targets INR500 crores plus in revenue over the next 4–5 years, with gross margins in the 45%–50% range and the NCE portfolio carrying even higher margins.
- Volume ramp timing: Real commercial volumes are expected to start trickling in and ramping up in another 2 quarters, though FY27 utilization will increase only modestly while awaiting global customer approvals.
- Personal Care commercialization: Two products were commercialized during Q3, with volume ramp-up expected over the next 9–12 months; 3–4 additional products are on track for FY27, and meaningful revenue begins next fiscal year.
- Distributor network built: Distributors were onboarded in Europe, Latin America, and the Middle East during the quarter, laying the go-to-market foundation for the segment.
- Additional tie-ups sought: Management is actively looking at additional tie-ups in Animal Health in the near future.
CDMO Pipeline & New Capabilities
- NCE progression: Hikal has been in the NCE business for several years; a couple of products are already commercialized, with bigger ones in Phase III moving toward launch in the next 1–2 years.
- CDMO engagement model: The company typically gets involved in early Phase II, supplies clinical trial quantities through Phase IIa, IIb, and Phase III, then supports commercial launch.
- Milvexian KSM supply: Hikal will supply the key starting material for Milvexian, with product launch scheduled for next year in FY27.
- HPAPI lab operational: A state-of-the-art high-potency laboratory and R&D centre in Pune is now operational, with Phase I investment of INR10–11 crores; a commercial-scale plant is planned for FY28, common for HP APIs and ADCs.
- ADC services begun: The company has started offering ADC services at lab scale, with the lab recently receiving OEB 5 certification.
- New pilot plant: A new pilot plant at the FDA-approved Panoli manufacturing site is now operational.
- Food & nutraceutical peak: Two custom products in the food and nutraceutical segment are on track to achieve peak output in FY27. [7-8]
- New generation niches: Management is moving into ADCs and food ingredient products, targeting 3–4 niches to ramp up over the next 3–4 years.
Sameer Hiremath: "This is a permanent upgrade to our organizational DNA designed to ensure long-term operational resilience and excellence."
Crop Protection: Persistent Headwinds
- Pricing pressure from China: The pricing environment remains highly competitive due to overcapacity and aggressive Chinese pricing, keeping margins under sustained pressure.
- Flattish outlook: Management maintained its guidance of flattish YoY performance for FY26, with stability expected on an annualized basis but no near-term recovery signaled.
- Repurposing plan: A crop plant is being repurposed in phases: Phase I will be implemented in the next 6 months, Phase II in the following 12 months, with the entire plant repurposed within 6–18 months and ramp-up possible in 6–9 months thereafter.
- Tariff uncertainty fading: U.S. tariff uncertainty had deferred customer procurement decisions for new projects; with that uncertainty now largely resolved, business should resume and orders should start coming in.
Financial Position & Capital Allocation
- Finance cost down 17% YoY: Lower debt and lower interest rates drove the reduction, improving the bottom line.
- Exceptional item drove reported loss: INR38 crores was provided as an exceptional item for new labor code charges notified on November 21, 2025, resulting in a loss for the quarter despite operational profitability.
- Capex discipline: FY26 capex will end at approximately INR150 crores; going forward, spending will be limited to debottlenecking and adding production lines based on customer contracts, with no major new capex planned.
- Debt reduction trajectory: From FY29 onwards, overall debt should begin to decline meaningfully as the current investment cycle matures and capex stays restrained.
- Interim dividend: The board approved an interim dividend of INR0.2 per share, representing 10% of face value.
Sameer Hiremath: "From FY '29 onwards, we should start seeing a reduction in overall debt, which is already reducing compared to where we were. We are not doing any major new capex or anything. It's debottlenecking, adding a production line here and there."
Margins & Operating Leverage
- New products structurally better: All new products carry gross margins slightly better than the company's historical gross margin, and because fixed cost absorption is already happening on the current base business, this flows directly to far better EBITDA.
- Pharma EBIT rebounding: Pharma EBIT margins are recovering after the regulatory-driven trough, while Crop business EBIT has been depressed for several quarters and continues to drag on total company EBIT.
- Operating leverage timeline: FY27 benefits once the FDA issue resolves and multiple products launch in the second half; Animal Health ramps up by FY28; Personal Care contributes from FY27 second half into FY28, all within existing assets requiring only marginal balancing equipment.
- Q4 expected better than Q3: Management stated Q4 will improve on Q3, driven by better demand visibility, improved capacity utilization, and new product commercialization ramping up.
Sameer Hiremath: "So even the margins from a gross margin perspective, the new products have a slightly better gross margin than the historical gross margin of the company, number one. But that directly flows down to far better EBITDA because fixed cost absorption is already happening on the current base business."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Pharma double-digit growth | Double-digit growth to begin in early part of FY27 | FY27 |
| Personal Care meaningful revenue | Meaningful revenue to commence | FY27 |
| Personal Care product launches | 3–4 products to be commercialized | FY27 |
| Milvexian KSM launch | Supply of key starting material for Milvexian | FY27 |
| Food & nutraceutical peak output | Two custom products at peak output | FY27 |
| Crop plant repurposing Phase I | Phase I implementation | Next 6 months |
| Crop plant repurposing Phase II | Phase II implementation | Next 12 months after Phase I |
| HPAPI commercial plant | Commercial-scale plant for HP APIs and ADCs | FY28 |
| Animal Health INR500 cr+ target | INR500 crores plus revenue | Next 4–5 years |
| Debt reduction | Overall debt to begin declining meaningfully | FY29 onwards |
| Capex FY26 | Approximately INR150 crores | FY26 |
Key Metrics
| Metric | Q3 FY26 |
|---|---|
| Consolidated revenue | ₹494 cr |
| Consolidated EBITDA | ₹83 cr, margin of 16.8% |
| Consolidated revenue (9M FY26) | ₹1,193 cr |
| Consolidated EBITDA (9M FY26) | ₹115 cr, margin of 9.6% |
| Profit before tax (adjusted) | ₹29 cr, grew 21% after adjusting for exceptional item |
| Exceptional item | ₹38 cr provision for new labour code charges notified Nov 21, 2025 |
| Finance cost | ₹48 cr, reduction of 17% YoY |
| Capital expenditure (9M FY26) | ₹100 cr; full-year FY26 guidance cut to ₹150 cr from ₹200 cr |
| Debt-equity ratio | 0.58 as on Dec 31, 2025 |
| Interim dividend | ₹0.2 per share, 10% of face value |
| Pharma division revenue | ₹337 cr |
| Pharma division EBIT | ₹41 cr, margin of 12.3% |
| Crop Protection division revenue | ₹157 cr |
| Crop Protection division EBIT | ₹5 cr, margin of 3% |
| Pharma volume growth | ~4% in Q3; double-digit volume growth expected to return |
| Animal Health gross margin | 45% to 50%, in line with company; NCE portfolio margins higher |
| Working capital reduction (9M FY26 vs Mar 25) | ~₹50 cr |
| HPAPI lab investment (Phase I) | ₹10–11 cr |
| Personal Care products commercialized in Q3 | 2 products; volume ramp-up over next 9–12 months |
| Pharma development pipeline (advanced stages) | 8 to 9 molecules |
| Crop Protection development pipeline | 8 products |